<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Pharmacy/Drugs-and-Medications/C/Capecitabine.html">
<title>Capecitabine RSS : Gourt</title>
<link>http://www.gourt.com/Health/Pharmacy/Drugs-and-Medications/C/Capecitabine.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2009-11-04T18:26+33:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Capecitabine RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://twitter.com/trialscentral/statuses/5428496972" />
  <rdf:li rdf:resource="http://twitter.com/trialscentral/statuses/5397624438" />
  <rdf:li rdf:resource="http://twitter.com/vqde1jz/statuses/5385218015" />
  <rdf:li rdf:resource="http://twitter.com/IPThinkTank/statuses/5250593279" />
  <rdf:li rdf:resource="http://twitter.com/MDLinx/statuses/5178106893" />
  <rdf:li rdf:resource="http://twitter.com/cancernetwrk/statuses/5171345800" />
  <rdf:li rdf:resource="http://twitter.com/research_papers/statuses/5169332970" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://twitter.com/trialscentral/statuses/5428496972">
<title>Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent   http://bit.ly/3oAEvK</title>
<link>http://twitter.com/trialscentral/statuses/5428496972</link>
<description><![CDATA[Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent   http://bit.ly/3oAEvK]]></description>
</item>

<item rdf:about="http://twitter.com/trialscentral/statuses/5397624438">
<title>Study With Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer  http://bit.ly/2sVEou</title>
<link>http://twitter.com/trialscentral/statuses/5397624438</link>
<description><![CDATA[Study With Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer  http://bit.ly/2sVEou]]></description>
</item>

<item rdf:about="http://twitter.com/vqde1jz/statuses/5385218015">
<title>1 Patient Information 2 XELODA (capecitabine) TABLETS 3 Rx only 4... http://tinyurl.com/yezhqwo</title>
<link>http://twitter.com/vqde1jz/statuses/5385218015</link>
<description><![CDATA[1 Patient Information 2 XELODA (capecitabine) TABLETS 3 Rx only 4... http://tinyurl.com/yezhqwo]]></description>
</item>

<item rdf:about="http://twitter.com/IPThinkTank/statuses/5250593279">
<title>Xeloda (Capecitabine) - US: Hoffmann-La Roche files patent infringement suit against Teva following Para IV challenge http://cli.gs/JX3Xz</title>
<link>http://twitter.com/IPThinkTank/statuses/5250593279</link>
<description><![CDATA[Xeloda (Capecitabine) - US: Hoffmann-La Roche files patent infringement suit against Teva following Para IV challenge http://cli.gs/JX3Xz]]></description>
</item>

<item rdf:about="http://twitter.com/MDLinx/statuses/5178106893">
<title>Heme/Onc: A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as http://url4.eu/eY9a</title>
<link>http://twitter.com/MDLinx/statuses/5178106893</link>
<description><![CDATA[Heme/Onc: A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as http://url4.eu/eY9a]]></description>
</item>

<item rdf:about="http://twitter.com/cancernetwrk/statuses/5171345800">
<title>Neoadjuvant Capecitabine Added to Standard Treatment Helps to Eradicate Tumors in Patients http://bit.ly/2dWJFE</title>
<link>http://twitter.com/cancernetwrk/statuses/5171345800</link>
<description><![CDATA[Neoadjuvant Capecitabine Added to Standard Treatment Helps to Eradicate Tumors in Patients http://bit.ly/2dWJFE]]></description>
</item>

<item rdf:about="http://twitter.com/research_papers/statuses/5169332970">
<title>EGF61A&#x3E;G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplat...: - http://tinyurl.com/yjqlkgt</title>
<link>http://twitter.com/research_papers/statuses/5169332970</link>
<description><![CDATA[EGF61A&gt;G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplat...: - http://tinyurl.com/yjqlkgt]]></description>
</item>

</rdf:RDF>